Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 12/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.42 |
| ▸ | MERTK | Q12866 | 5/20 | 0.42 |
| ▸ | FLT3 | P36888 | 4/20 | 0.42 |
| ▸ | GAS6 | Q14393 | 4/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4979254 | 0.89 | TTK (0.58) | TTKTYRO3MERTKFLT3GAS6 | |
| SCHEMBL4979267 | 0.88 | TTK (0.51) | TTKTYRO3MERTKAXLLRRK2 | |
| SCHEMBL4766935 | 0.87 | TTK (0.45) | TTKLRRK2 | |
| SCHEMBL4766540 | 0.86 | TTK (0.57) | TTK | |
| SCHEMBL4979599 | 0.83 | MERTK (0.51) | TTKMERTKAXLSYK | |
| SCHEMBL4974126 | 0.82 | TTK (0.45) | TTKMERTKLRRK2 | |
| SCHEMBL4973381 | 0.82 | TTK (0.46) | TTKMERTKSYK | |
| SCHEMBL2947265 | 0.81 | TTK (0.59) | TTK | |
| SCHEMBL4975548 | 0.81 | TTK (0.59) | TTK | |
| SCHEMBL2947263 | 0.81 | TTK (0.59) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | TTK 4589/4885TYRO3 2982/4885MERTK 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.